EOS IMAGING

EOS IMAGING is a French medical-device company headquartered in Paris that focuses on orthopedic and musculoskeletal imaging. Its technology is built around biplanar radiography: two X-ray images are captured simultaneously from approximately perpendicular directions while a patient is standing or sitting in a functional, weight-bearing position. Specialized software can then use those images to produce three-dimensional representations of the skeleton and calculate clinical measurements relevant to diagnosis, treatment planning, surgery, and postoperative follow-up. The company’s origins lie in the work of physicist Georges Charpak, whose research into radiation detection and particle-physics instrumentation, including the multi-wire chamber, provided the scientific foundation for the imaging approach. The business began in 1989 under the name Biospace Med. Marie Meynadier became its chief executive in 1999 and helped develop a subsidiary and product activity focused on imaging solutions. Clinical testing of an EOS prototype was completed in hospitals in Paris and Brussels in 2004, followed by venture financing in 2005. The company subsequently moved from experimental development toward regulated clinical commercialization, obtaining European CE marking and United States Food and Drug Administration clearance for its imaging system and sterEOS workstation between 2007 and 2011. Biospace Med adopted the EOS imaging name in 2010. Early installations took place in European and North American hospitals between 2008 and 2010, and by 2011 the technology had entered clinical routines in medical centers across ten countries. EOS imaging expanded its international footprint through an Asian installation in 2012, market access developments in Vietnam, China, and South Korea, and an initial Brazilian contract in 2016. The reference material describes more than 300 EOS systems installed in 51 countries, including the United States, Japan, South Korea, China, and countries throughout the European Union. EOS IMAGING’s product philosophy centers on three objectives: reducing radiation exposure, making calculated clinical parameters useful and manipulable for clinicians, and improving the workflow linking imaging with orthopedic care. The company markets the EOS and EOSedge imaging platforms together with software and orthopedic solutions. The systems are designed for disorders and procedures involving the spine, hips, knees, lower limbs, and broader skeletal alignment. The sterEOS workstation generates patient-specific 3D models from EOS examinations, while kneeEOS, hipEOS, and spineEOS provide online planning environments for selected orthopedic procedures. Radiation-dose management is a central part of the brand’s positioning. The company promotes low-dose acquisition and a Micro Dose option intended for examinations requiring especially limited exposure. EOSedge is described as using photon-counting technology and Flex Dose capabilities to reduce radiation compared with a corresponding acquisition without that feature. These capabilities are particularly relevant to patients who require repeated imaging during growth, long-term orthopedic monitoring, or treatment and postoperative assessment. The company’s business scope extends beyond hardware. EOS imaging combines imaging equipment, image reconstruction, 3D modeling, clinical measurement, surgical planning, and patient-specific orthopedic workflow tools. Its 2013 acquisition of oneFIT Medical added expertise in surgical-planning software for spine, hip, and knee procedures, as well as patient-specific orthopedic cutting guides. Corporate and operational locations described in the reference material include Paris and Besançon in France, St. Paul in the United States, Montreal in Canada, Frankfurt in Germany, and Singapore. The available material does not establish the company’s current ownership, executive leadership, legal status, or operating status, so those fields remain unspe…

EOS IMAGING developed from scientific research into radiation detection associated with Georges Charpak, the French physicist who received the 1992 Nobel Prize in Physics. Charpak’s work, particularly research connected with the multi-wire chamber, supplied the conceptual and technical foundation for a new approach to medical radiography. The approach sought to obtain clinically useful images while reducing radiation exposure and preserving information about the body in a functional position. The company was founded in 1989 as Biospace Med. Its early work involved the development of detection technology and imaging applications. In 1999, Marie Meynadier became chief executive of Biospace Med and helped establish an imaging-focused activity dedicated to developing the EOS system. Physicists, engineers, radiologists, and orthopedic surgeons collaborated to turn the underlying detection research into a clinical imaging platform. Hospitals in Paris and Brussels completed clinical testing of an EOS prototype in 2004. The company began its first venture-capital fundraising in 2005, supporting the transition from prototype development to regulatory and commercial preparation. Between 2007 and 2011, the EOS system received European CE marking and United States FDA authorization for marketing, while the sterEOS 2D/3D workstation also obtained authorization for the U.S. market. Initial installations in European and North American hospitals and clinics took place from 2008 through 2010. By 2011, EOS had entered routine clinical use in medical centers in ten countries, including the United States, Canada, and Australia. Biospace Med changed its name to EOS imaging in 2010, aligning the corporate identity with its principal technology and commercial platform. The company entered the Euronext Paris market in 2012 under the symbol EOSI and also recorded its first installation in Asia. In 2013, EOS imaging acquired oneFIT Medical, a Besançon-based medical software engineering and manufacturing company. The acquisition broadened the company’s capabilities in surgical planning for spine, hip, and knee operations and in patient-specific orthopedic cutting guides. International development continued during the middle of the 2010s. EOS technology was introduced to Vietnam in 2014 through Bluelight and the Medic and Medic Hoa Hao facilities. In 2015, the company obtained certification in China and a designation in South Korea that supported further market development. EOS imaging entered Latin America in 2016 through its first contract in Brazil. The company subsequently described a worldwide installed base of more than 300 systems in 51 countries, with installations in North America, Asia, Europe, and other regions. In 2019, EOS imaging launched EOSedge, described as a new-generation imaging system using photon-counting technology. EOSedge extended the company’s platform strategy around lower-dose acquisition, rapid or efficient imaging workflows, and the generation of clinically useful three-dimensional skeletal information. The broader EOS offering combines upright or seated biplanar imaging with reconstruction software, calculated anatomical parameters, online 3D services, and procedure-specific planning applications. The company’s technology is intended primarily for orthopedic and musculoskeletal care. During an examination, a patient stands or sits inside an upright scanning cabin while a vertically moving arm acquires frontal and lateral images using two fine X-ray beams. The resulting weight-bearing images can be modeled into a three-dimensional representation of the spine, pelvis, lower limbs, or other skeletal structures. Clinicians may use these models for diagnosis, alignment assessment, preoperative planning, implant selection, postoperative evaluation, and longitudinal follow-up. Radiation reduction has remained a defining part of EOS imaging’s identity. The company associates its systems with the ALARA principle, which seeks to keep radiation exposure as low as reasonably achievable. The Micro Dose option is presented as a substantially lower-dose protocol than a typical low-dose EOS examination, while EOSedge’s Flex Dose technology is described as reducing radiation relative to acquisition without the feature. Alongside dose reduction, EOS emphasizes the relevance of clinical parameters and the integration of imaging into the orthopedic care pathway. The available reference material identifies corporate locations in Paris and Besançon, France; St. Paul, Minnesota; Montreal, Quebec; Frankfurt; and Singapore. It does not provide sufficient information to establish the company’s current ownership, management, or legal status.

1. 2019EOSedge launches

   The company launches EOSedge, a new-generation imaging system associated with photon-counting technology.

   Source
2. 2016First Latin American contract

   EOS imaging enters Latin America through its first contract in Brazil.

   Source
3. 2015Chinese and South Korean market clearances

   The company obtains certification in China and a South Korean designation supporting market expansion.

   Source
4. 2014Entry into Vietnam

   The EOS system is introduced to the Vietnamese market through Bluelight and the Medic and Medic Hoa Hao facilities.

   Source
5. 2013Acquisition of oneFIT Medical

   EOS imaging acquires oneFIT Medical, expanding into orthopedic surgical-planning software and patient-specific cutting-guide capabilities.

   Source
6. 2012Euronext Paris listing and first Asian installation

   EOS imaging enters Euronext Paris under the symbol EOSI and records its first installation in Asia.

   Source
7. 2011EOS enters routine clinical use in multiple countries

   The EOS system is reported to be integrated into clinical routines at medical centers in ten countries.

   Source
8. 2010Biospace Med adopts the EOS imaging name

   The company changes its name from Biospace Med to EOS imaging.

   Source
9. 2005First venture financing

   Biospace Med begins its first venture-capital fundraising round to support development and commercialization.

   Source
10. 2004Clinical testing of the EOS prototype is completed

    Hospitals in Paris and Brussels complete clinical testing of the EOS prototype.

    Source
11. 1999Marie Meynadier becomes chief executive of Biospace Med

    Meynadier takes leadership of Biospace Med and develops an imaging-focused subsidiary and activity around the EOS system.

    Source
12. 1992Georges Charpak receives the Nobel Prize in Physics

    Charpak’s radiation-detection research is recognized with the Nobel Prize in Physics; that scientific work later serves as a foundation for the EOS imaging approach.

    Source
13. 1989Biospace Med is founded

    The company begins as Biospace Med, founded by Georges Charpak to develop medical applications related to radiation-detection technology.

    Source

Low-dose, weight-bearing biplanar orthopedic imaging and 3D surgical-planning technology provider

• EOS SystemOrthopedic medical imaging system

  The EOS system is an upright biplanar X-ray platform designed for musculoskeletal and orthopedic imaging. It acquires frontal and lateral, weight-bearing images while a patient stands or sits in a scanning cabin. Software can use the paired images to create three-dimensional skeletal models and calculate anatomical parameters. The system is intended for diagnosis, alignment assessment, treatment planning, postoperative review, and longer-term follow-up, particularly for the spine, pelvis, hips, knees, and lower limbs.

• EOSedgeNext-generation orthopedic imaging system2019

  EOSedge is the company’s newer imaging platform, launched in 2019 and associated with photon-counting technology. It extends the EOS approach of acquiring functional, weight-bearing biplanar images and supporting three-dimensional skeletal reconstruction. EOSedge also incorporates Flex Dose capabilities, which the reference material describes as reducing radiation compared with the same acquisition without that feature. The platform is positioned for orthopedic diagnosis, planning, and clinical workflow integration.

• sterEOS2D/3D imaging workstation

  sterEOS is a workstation for generating patient-specific three-dimensional models from low-dose or Micro Dose EOS examinations. It supports modeling of the spine and lower limbs, automatically calculates clinical parameters, and can produce reports combining two-dimensional images with three-dimensional views. The resulting information may be used for diagnosis, postoperative assessment, follow-up, and export of anatomical biomarkers for preoperative planning.

• EOSappsOnline orthopedic surgical-planning software

  EOSapps is a group of online, three-dimensional planning applications connected to EOS examinations and the EOS Portal. The applications include spineEOS for spine procedures, hipEOS for total hip arthroplasty planning, and kneeEOS for total knee arthroplasty planning. EOS images are uploaded for preparation of a 3D model and planning dataset, allowing surgeons to review anatomy and simulate implant selection and positioning.

• Micro DoseLow-radiation imaging protocol

  Micro Dose is a lower-radiation examination option developed for the EOS platform. The reference material describes it as reducing exposure by approximately 5.5 times compared with a typical low-dose EOS protocol. It is intended to support situations in which patients may need repeated imaging, while retaining the platform’s use of upright or seated biplanar acquisition.

• 2019Launch of EOSedgeProduct launch

  EOS imaging was developing a new generation of imaging technology while maintaining its focus on low-dose, functional orthopedic examinations.

  What changed. The company launched EOSedge, associated with photon-counting technology and additional dose-management capabilities.

  Aftermath. EOSedge became the newer platform in the EOS product family and reinforced the company’s positioning around low-dose imaging and orthopedic workflow integration.

  Source
• 2013Acquisition of oneFIT MedicalM&A

  EOS imaging sought to connect diagnostic imaging with downstream orthopedic planning and surgical workflows.

  What changed. It acquired oneFIT Medical, a Besançon-based medical software engineering and manufacturing company specializing in planning for spine, hip, and knee procedures and patient-specific cutting guides.

  Aftermath. The transaction broadened EOS imaging’s offering beyond imaging hardware and reconstruction toward procedure planning and personalized orthopedic surgery support.

  Source
• 2012Public-market expansion and Asian market entryStrategy

  Following regulatory progress and initial installations in Europe and North America, EOS imaging pursued additional capital-market and geographic expansion.

  What changed. The company entered Euronext Paris under the EOSI symbol and established its first installation in Asia.

  Aftermath. The move supported the company’s international growth strategy and increased the visibility of the EOS platform outside its original European and North American markets.

  Source
• 2010Corporate rebranding from Biospace Med to EOS imagingStrategy

  The company had developed its principal commercial imaging platform under the Biospace Med name and was moving toward broader clinical commercialization.

  What changed. It changed its corporate name to EOS imaging, aligning the business identity with its core imaging technology.

  Aftermath. The EOS name became the public identity for the company’s imaging systems, software, and orthopedic solutions.

  Source

1. EOS imaging
2. EOS Imaging official website